Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
8.50    0.00 (0.00%)
Bid:
8.00
Ask:
9.00
Spread: 1.00 (12.50%)
Market Cap: £538.27m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Director/PDMR Shareholding

25 Oct 2005 14:27

Allergy Therapeutics PLC25 October 2005 SCHEDULE 11 NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS 1. Name of company ALLERGY THERAPEUTICS PLC 2. Name of director Andrew Turnbull 3. Please state whether notification indicates that it is in respect of holdingof the shareholder named in 2 above or in respect of a non-beneficial interestor in the case of an individual holder if it is a holding of that person'sspouse or children under the age of 18 or in respect of a non-beneficialinterest As above 4. Name of the registered holder(s) and, if more than one holder, the number ofshares held by each of them (if notified) Andrew Turnbull 5. Please state whether notification relates to a person(s) connected with thedirector named in 2 above and identify the connected person(s) N/A 6. Please state the nature of the transaction. For PEP transactions pleaseindicate whether general/single co PEP and if discretionary/non discretionary Acquisition of Shares 7. Number of shares / amount of stock acquired 10,421 8. Percentage of issued class 0.02 per cent. 9. Number of shares/amount of stock disposed N/A 10. Percentage of issued class N/A 11. Class of security Ordinary Shares of 0.1p each 12. Price per share 95 pence 13. Date of transaction 25 October 2005 14. Date company informed 25 October 2005 15. Total holding following this notification 221,819 16. Total percentage holding of issued class following this notification 0.35 per cent. If a director has been granted options by the company please complete thefollowing boxes. 17. Date of grant N/A 18. Period during which or date on which exercisable N/A 19. Total amount paid (if any) for grant of the option N/A 20. Description of shares or debentures involved: class, number N/A 21. Exercise price (if fixed at time of grant) or indication that price is to befixed at time of exercise N/A 22. Total number of shares or debentures over which options held following thisnotification N/A 23. Any additional information N/A 24. Name of contact and telephone number for queries 01903 844709 Francesca West 25. Name and signature of authorised company official responsible for makingthis notification Andrew Turnbull Date of Notification 25 October 2005 The FSA does not give any express or implied warranty as to the accuracy of thisdocument or material and does not accept any liability for error or omission.The FSA is not liable for any damages (including, without limitation, damagesfor loss of business or loss of profits) arising in contract, tort or otherwisefrom the use of or inability to use this document, or any material contained init, or from any action or decision taken as a result of using this document orany such material. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
31st Mar 20267:00 amRNSInterim Results for six months ended 31 Dec 2025
12th Mar 20267:00 amRNSPDMR Dealings & Shareholding Update
12th Mar 20267:00 amRNSPDMR Dealings & Shareholding Update
4th Mar 20267:00 amRNSPositive Biomarker Results from PROTECT Trial
26th Feb 20267:00 amRNS-RAllergy Therapeutics presents progress at AAAAI
23rd Feb 20267:51 amRNSUpdate on funding and total voting rights
30th Jan 20268:22 amRNSChief Strategy Officer and Board appointments
29th Jan 20262:13 pmRNSResult of Annual General Meeting
28th Jan 20264:48 pmRNSGrant of Options under Long Term Incentive Scheme
19th Jan 20267:00 amRNSHalf Year Trading Update
6th Jan 20267:00 amRNSNotice of 2025 Annual General Meeting
29th Dec 20251:07 pmRNSResults of General Meeting
29th Dec 20251:07 pmRNSResults of General Meeting
16th Dec 20257:00 amRNSGrassmuno® marketing authorisation in Germany
12th Dec 20257:00 amRNSAuthority for allotment of New Shares
11th Dec 20257:00 amRNSPrelim Results and publication of Annual Report
9th Dec 20257:00 amRNSPrimary Safety Endpoint Met in PROTECT trial
6th Nov 20257:22 amRNSCompany to Evaluate Dual Listing on HKEX
30th Oct 20257:00 amRNSG308 Phase III Year 2 Patient Screening Starts
29th Oct 20257:00 amRNSWarrant Exercise and Paydown of Debt
16th Oct 20257:00 amRNSFurther progress in Phase I/IIa PROTECT trial
31st Jul 20257:00 amRNS-RGrass MATA MPL Publications in Allergy Journal
21st Jul 20257:00 amRNSTrading update for the year ended 30 June 2025
11th Jul 20257:00 amRNSPDMR Dealings
13th Jun 20257:00 amRNS-RAllergy Therapeutics presents findings at EAACI
10th Jun 20257:04 amRNS-REAACI Early Career Research Award
31st Mar 20257:00 amRNSInterim Results for six months ended 31 Dec 2024
27th Mar 20257:00 amRNSAdvancement to final phase of PROTECT trial
3rd Mar 20257:00 amRNSNew Executive Long Term Incentive Awards
27th Feb 20257:00 amRNS-RPresentations at 2025 AAAAI / WAO Joint Congress
17th Feb 20257:00 amRNSGrass MATA MPL Phase III data published in Allergy
14th Feb 20257:00 amRNSGrant of Options
28th Jan 20257:00 amRNSHalf Year Trading update
22nd Jan 20257:00 amRNSPDMR Dealing and Total Voting Rights
15th Jan 20257:00 amRNSDirector/PDMR Shareholding
19th Dec 20241:41 pmRNSExercise of Options and Total Voting Rights
17th Dec 20244:19 pmRNSBlock Listing Interim Review
16th Dec 20243:33 pmRNSResult of Annual General Meeting
4th Dec 20247:00 amRNSPositive Interim Data from PROTECT Trial
27th Nov 20247:00 amRNSFirst Patient Dosed in G308 Paediatric Trial
25th Nov 20247:00 amRNSSubmission of MAA for Grass MATA MPL
21st Nov 20247:00 amRNSNotice of 2024 Annual General Meeting
6th Nov 20247:00 amRNSAudited Preliminary Results 2024
21st Oct 20247:00 amRNSCommencement of Phase III Paediatric Trial
16th Oct 20247:00 amRNSUpdate on funding
1st Oct 20247:00 amRNSUpdate on funding and preliminary results
17th Sep 20247:00 amRNSProgression of patient cohorts in PROTECT Trial
27th Aug 20247:00 amRNSUpdate on funding
22nd Jul 20247:01 amRNSTrading update for the year ended 30 June 2024
22nd Jul 20247:00 amRNSAppointment of Nominated Adviser and Sole Broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.